Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERIOP-FOLFIRINOX in Locally Advanced Gastroesophageal Adenocarcinoma
NCT02366819Phase 4Suspended
- Sponsor
- University of Chicago
- Start
- Dec 2014
- Primary completion
- Jun 2026
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in gastroesophageal adenocarcinoma and gastric adenocarcinoma, sponsored by University of Chicago. Primary endpoints: Residual tumor (R) 0 resection rate and Pathologic complete response rate. Started Dec 2014; status: suspended.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
gastroesophageal adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on NCT02366819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02366819.